Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 May 11;28(1):920–929. doi: 10.1080/10717544.2021.1914777

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 2. — oHA competitively inhibited HA and increased the oxaliplatin sensitivity of RKO cells. (A,B) Competitive inhibition of HA by oHA in RKO cells. CD44v6 was cross-linked by BS3 treatment. When the HA synthase inhibitors 4-MU and hyaluronidase were added, the expression of CD44v6 at 170 kDa decreased, indicating that cross-linking of CD44v6 requires HA. Adding oHA, the expression of cross-linked protein is also reduced, indicating that oHA competitively inhibits HA. (C) RKO cell sensitivity to oxaliplatin in the presence versus absence of oHA treatment (*p < .05, oHA + Oxa vs. Oxa). (D-E) Flow cytometry analysis of the effect of oHA on oxaliplatin sensitivity. Oxaliplatin combined with oHA produced greater sensitivity than did oxaliplatin alone (*p < .001).